研究单位：[1]Changchun Huayang High-tech Co.,Ltd[2]First Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]Affiliated Hospital of Guilin Medical University Guilin,Guangxi,China[4]Hebei mental health center Baoding,Hebei,China[5]Jiangsu Province Hospital Nanjing,Jiangsu,China[6]The first Affiliated Hospital of Jilin University Changchun,Jilin,China[7]The First Affiliated Hospital of Medical School of Zhejiang University Hangzhou,Zhejiang,China[8]Beijing HuiLongGuan Hospital Beijing,China[9]Beijing Shijitan Hospital,EMU Beijing,China[10]Shanghai Changzheng Hospital Shanghai,China
研究目的：
The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.
